P. Travis

c-myc transcription is initiated from P0 in 70% of patients with multiple myeloma.

V. Kaushal, R. Hoover, T. Sneed, 1995, Current topics in microbiology and immunology.

An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

J. Copland, D. V. Von Hoff, L. Marlow, 2011, Journal of Cancer.

O-263 Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP) - ACR 427

W. Curran, H. Choy, P. Bonomi, 2003 .

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

J. Burke, K. Kolibaba, I. Flinn, 2021, The Lancet. Haematology.

Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

B. Barlogie, R. Owens, R. Hoover, 1995, The Journal of clinical investigation.

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

S. Kambhampati, J. Burke, I. Flinn, 2017 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .

Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Walter J Curran, Hak Choy, W. Curran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mode of chemotherapy does not affect complications with an implantable venous access device

M. Hauer-Jensen, P. Travis, M. Muirhead, 1997, Cancer.